

**CHI Federal Legislative Committee
Meeting Agenda**

Thursday, June 6, 2013
11:00 a.m. Eastern / 8:00 a.m. Pacific
Call In: 1-866-210-1669
Guest Code: 1453428#

Moderator: Jenny Carey

1. Introductions
2. Antitrust Statement – *see below*
3. General Congressional Overview/Update
4. Issues/Advocacy
 - a. Medical Device Excise Tax Repeal – *see [Letter to Editor](#) of [LA Times](#)*
 - b. Appropriations and User Fees
 - i. FDA Appropriations and User Fees – *see [link](#) or attached letter to Congress*
 - ii. USPTO User Fees – *see [link](#) or attached letter to Congress*
 - c. House/Senate Track and Trace Draft Legislation – *see attached policy statement*
 - i. Preemption/Uniform National Policy
 - ii. Other provisions of interest
 - d. Immigration Reform
 - e. Patent Reform
 - f. Other
5. Events/Activities
 - a. Frosh Class Meet-and-Greets
 - i. Rep. Julia Brownley – June 18th – *see attached invitation*
 - ii. Rep. Tony Cardenas – June 20th – *see attached invitation*
 - iii. Future events – Rep. David Valadao (TBD)
 - b. California Delegation Life Science “101” Briefings
 - i. Medical Devices – May 20th (Report)
 - ii. Biosimilars – June 24th
 - iii. Public-private partnerships and role in biomedical innovation – TBD
 - c. Multi-State Associations House/Senate Briefings: “Value of Biomedical Innovation” – June 4 (Report)
 - d. CHI Q3 Event: “Pipeline for Life” – July 15th at Salk Institute, La Jolla
6. Other Business

CHI Antitrust Statement

The California Healthcare Institute (CHI) is an independent organization devoted to researching and advocating policy to forward the interests of California's biomedical community. CHI's membership includes biomedical companies, academic and research institutions, and companies involved in supporting the life sciences community.

CHI meetings are held for the purpose of transacting the appropriate business of the Institute and to further its legitimate goals. All CHI meetings shall therefore be conducted to strictly abide by all applicable antitrust laws. Meetings attended by CHI members or hosted by CHI are not to be used to discuss prices, promotions, refusals to deal, boycotts, terms and conditions of sale, market assignments, confidential business plans, or other subjects that could restrain competition. Compliance with these guidelines is essential if CHI is to effectively represent its members.

Antitrust violations do not require proof of a formal agreement. A violation may be alleged based upon the mere appearance of unlawful activity. For example, discussion of a sensitive topic, such as price, followed by parallel action by those involved or present at the discussion, may be sufficient to show a price-fixing conspiracy.

The harsh penalties contained in antitrust laws (fines up to \$10,000,000 for corporations per violation and fines up to \$350,000 and/or imprisonment for one year for individuals), the high costs of defending antitrust lawsuits, and the devastating impact of treble damage actions mandate prudent conservative policies and practices regarding antitrust compliance by CHI and its members.

By following the guidelines set forth herein, CHI and its members can minimize antitrust risks and meet to transact lawful Institute business.